CX Institutional’s SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10K | Sell |
247
-18,394
| -99% | -$745K | ﹤0.01% | 1045 |
|
|
2025
Q1 | $816K | Buy |
18,641
+8,458
| +83% | +$370K | 0.03% | 300 |
|
|
2024
Q4 | $438K | Buy |
+10,183
| New | +$438K | 0.02% | 367 |
|
|
2024
Q3 | – | Sell |
-9,711
| Closed | -$386K | – | 600 |
|
|
2024
Q2 | $386K | Buy |
9,711
+5,240
| +117% | +$208K | 0.02% | 405 |
|
|
2024
Q1 | $193K | Buy |
+4,471
| New | +$193K | 0.01% | 526 |
|
|
2023
Q3 | – | Sell |
-20,113
| Closed | -$824K | – | 559 |
|
|
2023
Q2 | $824K | Buy |
20,113
+613
| +3% | +$25.1K | 0.04% | 298 |
|
|
2023
Q1 | $805K | Buy |
+19,500
| New | +$805K | 0.04% | 306 |
|
|
2022
Q4 | – | Sell |
-78,878
| Closed | -$3.17M | – | 584 |
|
|
2022
Q3 | $3.17M | Buy |
78,878
+78,686
| +40,982% | +$3.16M | 0.22% | 110 |
|
|
2022
Q2 | $8K | Buy |
+192
| New | +$8K | ﹤0.01% | 987 |
|
|
2021
Q4 | – | Sell |
-896
| Closed | -$43K | – | 914 |
|
|
2021
Q3 | $43K | Sell |
896
-42,688
| -98% | -$2.05M | ﹤0.01% | 613 |
|
|
2021
Q2 | $2.26M | Buy |
43,584
+42,818
| +5,590% | +$2.22M | 0.19% | 136 |
|
|
2021
Q1 | $39K | Sell |
766
-1,069
| -58% | -$54.4K | ﹤0.01% | 546 |
|
|
2020
Q4 | $95K | Sell |
1,835
-35,334
| -95% | -$1.83M | 0.01% | 368 |
|
|
2020
Q3 | $1.62M | Sell |
37,169
-3,383
| -8% | -$147K | 0.17% | 150 |
|
|
2020
Q2 | $1.74M | Buy |
40,552
+40,485
| +60,425% | +$1.74M | 0.23% | 122 |
|
|
2020
Q1 | $2K | Sell |
67
-29
| -30% | -$866 | ﹤0.01% | 697 |
|
|
2019
Q4 | $4K | Hold |
96
| – | – | ﹤0.01% | 607 |
|
|
2019
Q3 | $3K | Sell |
96
-77
| -45% | -$2.41K | ﹤0.01% | 702 |
|
|
2019
Q2 | $7K | Sell |
173
-29,830
| -99% | -$1.21M | ﹤0.01% | 560 |
|
|
2019
Q1 | $1.25M | Buy |
30,003
+29,981
| +136,277% | +$1.25M | 0.22% | 114 |
|
|
2018
Q4 | $1K | Buy |
+22
| New | +$1K | ﹤0.01% | 522 |
|
|
2018
Q3 | – | Sell |
-12,557
| Closed | -$540K | – | 362 |
|
|
2018
Q2 | $540K | Buy |
+12,557
| New | +$540K | 0.2% | 94 |
|